Drugs / Tosedostat
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01636609 | Nov 2012 → Jul 2019 | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01638442 | Jun → Jul 2012 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT00737555 | Aug 2006 → Mar 2008 | cancer | Chroma Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00692354 | Oct 2004 → Nov 2007 | cancer | Chroma Therapeutics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02352831 | Aug 2015 → Oct 2017 | malignant pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00522938 | Dec 2007 → Feb 2008 | non-small cell lung carcinoma | Chroma Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00689000 | May 2006 → Dec 2007 | acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | Chroma Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02452346 | Mar 2015 → Oct 2017 | myelodysplastic syndrome | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT01567059 | May 2012 → Jun 2013 | acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with multilineage dysplasia, acute myeloid leukemia, del(5q31-q32), myelodysplastic syndrome | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01180426 | Jun 2010 → Jun 2013 | acute myeloid leukemia | Chroma Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT00780598 | Oct 2009 → Mar 2011 | acute myeloid leukemia | Chroma Therapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tosedostat | “An Open-label, Randomized, Two-way Crossover Trial of the Effect of a High-Fat Meal on the Pharmacokinetics of Oral Tosedostat (CHR 2797) in Healthy Male Subjects” NCT01638442 ↗8“Proposed INN: tosedostat” NCT00737555 ↗ “CHR-2797 (tosedostat)” NCT00692354 ↗ “CHR-2797 (tosedostat)” NCT00522938 ↗ |
| Known as | CHR 2797 | “An Open-label, Randomized, Two-way Crossover Trial of the Effect of a High-Fat Meal on the Pharmacokinetics of Oral Tosedostat (CHR 2797) in Healthy Male Subjects” NCT01638442 ↗ |
| Action | Inhibit | “Aminopeptidase Inhibitor” NCT00692354 ↗ |
| Modality | Small molecule | — CHEMBL2103847 ↗ |
| Route | Oral | “Once daily, oral ingestion of CHR-2797 capsules” NCT00522938 ↗ |